109.50Open109.50Pre Close0 Volume1 Open Interest150.00Strike Price0.00Turnover99.96%IV3.04%PremiumDec 20, 2024Expiry Date101.84Intrinsic Value100Multiplier17DDays to Expiry7.66Extrinsic Value100Contract SizeAmericanOptions Type0.9942Delta0.0003Gamma2.46Leverage Ratio-0.0423Theta0.0688Rho2.45Eff Leverage0.0090Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet